Skip to main content
SpringerLink
Log in

The Current Role of Plerixafor in Stem Cell Mobilization for Hematopoietic Stem Cell Transplantation

  • Chapter
  • First Online:
Novel Developments in Stem Cell Mobilization

Abstract

Granulocyte colony-stimulating factor has been the traditional agent used for mobilization of stem cells for hematopoietic stem cell (HSC) transplantation. Recently, plerixafor, an inhibitor of the interaction between CX chemokine receptor 4 (CXCR4) and stromal derived factor-1α (SDF-1) has been evaluated in clinical trials and approved by the FDA. This agent has very modest toxicity but appears to be quite potent at HSC mobilization. The rationale for the use of this agent and the clinical trials in which it was evaluated are the subject of this review.

Amy R. MacKenzie and Matias E. Valsecchi contributed equally to the preparation of this review.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A, Liso V, Perrone T, Liso A (2006) Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 37:719–724

    Article  PubMed  CAS  Google Scholar 

  2. Bensinger W, DiPersio JF, McCarty JM (2009) Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 43:181–195

    Article  PubMed  CAS  Google Scholar 

  3. Shpall EJ (1999) The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant 23(Suppl 2):S13–S19

    Article  PubMed  Google Scholar 

  4. Kuittinen T, Nousiainen T, Halonen P, Mahlamaki E, Jantunen E (2004) Prediction of mobilisation failure in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant 33:907–912

    Article  PubMed  CAS  Google Scholar 

  5. Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J, Arenzana-Seisdedos F, Magerus A, Caruz A, Fujii N, Nagler A, Lahav M, Szyper-Kravitz M, Zipori D, Lapidot T (2000) Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 106:1331–1339

    Article  PubMed  CAS  Google Scholar 

  6. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3:687–694

    Article  PubMed  CAS  Google Scholar 

  7. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, Jackson JB, Coombs RW, Glesby MJ, Flexner CW, Bridger GJ, Badel K, MacFarland RT, Henson GW, Calandra G, AMD3100 HIV Study Group (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37:1253–1262

    Article  PubMed  CAS  Google Scholar 

  8. Hess DA, Bonde J, Craft TP, Wirthlin L, Hohm S, Lahey R, Todt LM, Dipersio JF, Devine SM, Nolta JA (2007) Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant 13:398–411

    Article  PubMed  CAS  Google Scholar 

  9. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, Liles WC, Li X, Graham-Evans B, Campbell TB, Calandra G, Bridger G, Dale DC, Srour EF (2005) Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201:1307–1318

    Article  PubMed  CAS  Google Scholar 

  10. Martin C, Bridger GJ, Rankin SM (2006) Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro. Br J Haematol 134:326–329

    Article  PubMed  CAS  Google Scholar 

  11. Burroughs L, Mielcarek M, Little MT, Bridger G, Macfarland R, Fricker S, Labrecque J, Sandmaier BM, Storb R (2005) Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 106:4002–4008

    Article  PubMed  CAS  Google Scholar 

  12. Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S, Bridger G, Dunbar CE, Hematti P (2006) AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 107:3772–3778

    Article  PubMed  CAS  Google Scholar 

  13. Peled A, Grabovsky V, Habler L, Sandbank J, Arenzana-Seisdedos F, Petit I, Ben-Hur H, Lapidot T, Alon R (1999) The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest 104:1199–1211

    Article  PubMed  CAS  Google Scholar 

  14. Lack NA, Green B, Dale DC, Calandra GB, Lee H, MacFarland RT, Badel K, Liles WC, Bridger G (2005) A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther 77:427–436

    Article  PubMed  CAS  Google Scholar 

  15. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, Hangoc G, Bridger GJ, Henson GW, Calandra G, Dale DC (2003) Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102:2728–2730

    Article  PubMed  CAS  Google Scholar 

  16. Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G, Christensen J, Wood B, Price TH, Dale DC (2005) Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 45:295–300

    Article  PubMed  CAS  Google Scholar 

  17. Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K, Calandra G, DiPersio JF (2004) Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J Clin Oncol 22:1095–1102

    Article  PubMed  CAS  Google Scholar 

  18. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G (2005) The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106:1867–1874

    Article  PubMed  CAS  Google Scholar 

  19. Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G (2009) Treatment with plerixafor in non-Hodgkin’s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 15:249–256

    Article  PubMed  CAS  Google Scholar 

  20. Tricot G, Cottler-Fox MH, Calandra G (2010) Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 45:63–68

    Article  PubMed  CAS  Google Scholar 

  21. Gazitt Y, FreytesCO AC, Badel K, Calandra G (2007) Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin’s lymphoma patients. Stem Cells Dev 16:657–666

    Article  PubMed  CAS  Google Scholar 

  22. Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, DiPersio J (2008) A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 14:1253–1261

    Article  PubMed  CAS  Google Scholar 

  23. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G, 3101 Investigators (2009) Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol 27:4767–4773

    Article  PubMed  CAS  Google Scholar 

  24. Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G, Calandra G (2009) Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 15:1578–1586

    Article  PubMed  CAS  Google Scholar 

  25. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra G, 3102 Investigators (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113:5720–5726

    PubMed  CAS  Google Scholar 

  26. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF (2008) Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 14:1045–1056

    Article  PubMed  CAS  Google Scholar 

  27. Duarte RF, Shaw BE, Marin P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martinez-Chamorro C, Mateos-Mazon JJ, Ramirez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH (2011) Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 46:52–58

    Article  PubMed  CAS  Google Scholar 

  28. Hubel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rosler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kroger N (2010) Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2010. doi:10.1038/bmt.2010.249

  29. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, Grove B, Dye A, Bridger G (2008) AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 41:331–338

    Article  PubMed  CAS  Google Scholar 

  30. Andreeff M, Konoplev S, Wong R-Y et al (2006) Massive mobilization of AML cells into circulation by disruption of leukemia/stroma cell interactions using CXCR4 antagonist AMD3100: first evidence in patients and potential for abolishing bone marrow microenvironment-mediated resistance [abstract]. Blood 108:176a

    Google Scholar 

  31. Fierro FA, Brenner S, Oelschlaegel U et al (2009) Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia. Leukemia 23:393–396

    Article  PubMed  CAS  Google Scholar 

  32. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G (2010) Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin’s lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 45:39–47

    Article  PubMed  CAS  Google Scholar 

  33. Flomenberg N, Comenzo RL, Badel K, Calandra G (2010) Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. Biol Blood Marrow Transplant 16:695–700

    Article  PubMed  CAS  Google Scholar 

  34. Jagasia MH, Savani BN, Neff A, Dixon S, Chen H, Pickard AS (2010) Outcome, toxicity profile and cost analysis of autologous stem cell mobilization. Bone Marrow Transplant. doi:10.1038/bmt.2010.254

  35. Gertz MA, Wolf RC, Micallef IN, Gastineau DA (2010) Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 45:1396–1403

    Article  PubMed  CAS  Google Scholar 

  36. Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354:1813–1826

    Article  PubMed  CAS  Google Scholar 

  37. Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, Devine H, Link DC, Calandra G, Bridger G, Westervelt P, Dipersio JF (2008) Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 112:990–998

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thomas Jefferson University, 834 Chestnut Street, Suite 320, Philadelphia, PA, 19107, USA

    Amy R. MacKenzie, Matias E. Valsecchi & Neal Flomenberg

Authors
  1. Amy R. MacKenzie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matias E. Valsecchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neal Flomenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neal Flomenberg .

Editor information

Editors and Affiliations

  1. , Zentrum für Tumordiagnostik und –therapi, Paracelsus-Klinik, Am Natruper Holz 69, Osnabrück, 49076, Germany

    Stefan Fruehauf

  2. Deutsches Krebsforschungszentrum (G360), Im Neuenheimer Feld 280, Heidelberg, 69120, Germany

    W. Jens Zeller

  3. Private, Cresco, 18326, Pennsylvania, USA

    Gary Calandra

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

MacKenzie, A.R., Valsecchi, M.E., Flomenberg, N. (2012). The Current Role of Plerixafor in Stem Cell Mobilization for Hematopoietic Stem Cell Transplantation. In: Fruehauf, S., Zeller, W., Calandra, G. (eds) Novel Developments in Stem Cell Mobilization. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-1960-0_7

Download citation

Publish with us

Policies and ethics

Search

Navigation